Lexicon Pharmaceuticals (LXRX) director buys 150,000 common shares

Rhea-AI Filing Summary

Lexicon Pharmaceuticals director Raymond Debbane reported buying 150,000 shares of common stock in open-market transactions. On February 19, he purchased 50,000 shares at a weighted average price of $1.4393 per share, and on February 20 he bought 100,000 shares at a weighted average price of $1.4779 per share.

After these purchases, his directly owned stake increased to 1,804,186 common shares. The filing also reports additional common stock positions as indirectly owned through entities including Avicenna Life Sci Master Fund LP, Invus Public Equities, L.P., Invus US Partners, LLC, and Invus, L.P.

Insider Trade Summary

Net Buyer: 150,000 shares ($219,755)

Net Buy 6 txns

Insider DEBBANE RAYMOND

Role Director

Bought 150,000 shs ($220K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	100,000	$1.4779	$148K
Purchase	Common Stock	50,000	$1.4393	$72K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,804,186 shares (Direct); Common Stock — 1,538,462 shares (Indirect, By Avicenna Life Sci Master Fund LP and related parties)

Footnotes (1)

1. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEBBANE RAYMOND

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD.

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		P		50,000	A	$1.4393(1)	1,704,186	D
Common Stock	02/20/2026		P		100,000	A	$1.4779(2)	1,804,186	D
Common Stock								1,538,462	I	By Avicenna Life Sci Master Fund LP and related parties
Common Stock								7,362,368	I	By Invus Public Equities, L.P. and related parties
Common Stock								5,451,204	I	By Invus US Partners, LLC and related parties
Common Stock								35,402,689	I	By Invus, L.P. and related parties

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

2. Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.

	/s/ Raymond Debbane	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lexicon Pharmaceuticals (LXRX) report for Raymond Debbane?

Raymond Debbane reported open-market purchases of Lexicon Pharmaceuticals common stock totaling 150,000 shares. He bought 50,000 shares on February 19, 2026 and 100,000 shares on February 20, 2026, as disclosed in a Form 4 insider trading report.

At what prices did Raymond Debbane buy Lexicon Pharmaceuticals (LXRX) shares?

He purchased shares at weighted average prices of $1.4393 and $1.4779 per share. The February 19, 2026 trade averaged $1.4393, while the February 20, 2026 trade averaged $1.4779, reflecting multiple individual transactions within each stated price range.

How many Lexicon Pharmaceuticals (LXRX) shares does Raymond Debbane own directly after these trades?

Following the reported purchases, Raymond Debbane directly owns 1,804,186 shares of Lexicon Pharmaceuticals common stock. This total reflects his position after buying 50,000 shares on February 19, 2026 and 100,000 additional shares on February 20, 2026 in the open market.

Were the Lexicon Pharmaceuticals (LXRX) insider trades by Raymond Debbane open-market purchases?

Yes, the Form 4 describes both transactions as open-market purchases coded “P.” The filing indicates they were made at weighted average prices, with detailed price ranges of $1.425–$1.455 and $1.47–$1.49 per share for the respective purchase dates.

What indirect holdings related to Lexicon Pharmaceuticals (LXRX) are reported for Raymond Debbane?

The filing lists indirect ownership of Lexicon Pharmaceuticals common stock through Avicenna Life Sci Master Fund LP and several Invus-related entities. Reported totals include 1,538,462; 7,362,368; 5,451,204; and 35,402,689 shares held by these affiliated investment entities.

How many total Lexicon Pharmaceuticals (LXRX) shares did Raymond Debbane buy in this Form 4?

He bought a total of 150,000 Lexicon Pharmaceuticals common shares. This consists of 50,000 shares purchased on February 19, 2026 and 100,000 shares bought on February 20, 2026, all recorded as open-market transactions at specified weighted average prices.